Apple Mac Mini deal: One of Apple's most powerful computers is also the cheapest
Buy the Apple Mac Mini M4 for just $539 ($60 off)
This offer is available from Amazon. It's specifically for the model with 16GB of RAM and 256GB of internal storage. Upgraded models are also discounted, though.
We would honestly recommend the Apple Mac Mini M4 at its full $599 price point. At $539, it is quite the steal for what you're getting. As already mentioned, it is one of Apple's best computers, unless you start moving to much higher-tier ones. It's an excellent computer.
Of course, this is a desktop PC, so it doesn't quite offer the portability of MacBooks. You'll need a mouse/trackpad, keyboard, and monitor. If you already have those, you're ready to go. Otherwise, you should definitely consider those extra expenses, too.
So, what makes it so special? It has the same Apple M4 chip and 16GB of RAM you'll find on the base MacBook Air and Pro models. That said, it will actually perform better than similarly spec'd laptops. This is mainly because it has much better active cooling, and the components aren't as crammed inside. A cooler computer can push higher loads for longer, as overheating can cause throttling. It should be able to handle any app, and many even use it for 4K editing.
The new Mac Mini got a really nice design overhaul. It is smaller, measuring 5 x 5 x 2 in. It will easily fit in any space, and it can also live under a TV, so you can also use it with a wireless keyboard and mouse in the living room. It's made of aluminum, following that iconic Apple design many of us love. It will look great anywhere.
Surprisingly, it has plenty of ports for its size. The front has two USB-C ports and a 3.5 mm headset jack. The back has two USB-C Thunderbolt ports, an Ethernet port, an HDMI output, and a power connection.
All things considered, and given the reasonable price, the Apple Mac Mini M4 is a fabulous little desktop computer. There is one thing people often complain about, though, and it is honestly a bit annoying. The power button is at the bottom, so you have to lift the Mac Mini to press it. The argument is that you would rarely turn it on or off, and would let it go to sleep instead. Still a weird placement for a power button, though.
Go catch this deal while you can! We don't know when the price will rise to $599.
Extra deals: The M2 and M4 MacBook Airs are also at a great price!
Apple MacBook Air 13-Inch (M2, 16GB, 256GB)
Apple MacBook Air 13-Inch (M2, 16GB, 256GB)
Thin, light, and powerful
The MacBook Air with an M2 chip brings the thin and lightweight design you'd expect from an Air, but with all the might of the M2 silicon.
See price at Best Buy
Save
$300.00
If you prefer a laptop form factor, Apple has some amazing deals available right now. The Apple MacBook Air M2 is the cheapest at just $699, which is a $200 discount. Honestly, it is amazingly good for that price. I personally own this model, and it can easily handle all my RAW photo editing and some 4K video processing. It will run any other task like a dream.
Now, if you absolutely want the latest and greatest, the Apple MacBook Air M4 comes with the newest chip and the same 16GB of RAM. Both laptops are nearly identical, with the exception that this one comes with the upgraded processor. This one goes for $999, which is also discounted by $200.
Follow
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
West Point Gold Engages VRIFY to Accelerate Exploration and Unlock Discovery at Gold Chain Project
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2025) - West Point Gold Corp. (TSXV: WPG) (OTCQB: WPGCF) (FSE: LRA0) ("West Point Gold" or the "Company") is pleased to announce that it has engaged VRIFY Technology Inc. ("VRIFY"), the leading provider of AI-assisted mineral discovery and 3D project visualization, to support and accelerate its exploration efforts across its Gold Chain Project in Arizona. West Point will harness VRIFY's full suite of products to maximize the value of its extensive datasets to drive smarter, faster discovery outcomes. DORA, the world's only AI-Assisted Mineral Discovery Platform, will support the Company in identifying, ranking, and validating targets using artificial intelligence. Viz, VRIFY's dynamic 3D visualization tool, will transform stakeholder engagement and elevate the clarity of technical storytelling. "Our team has always prioritized visual storytelling," said Quentin Mai, President & CEO of West Point Gold. "Partnering with VRIFY allows us to take our project presentations to the next level and more effectively showcase the potential of our Gold Chain Project to investors and stakeholders." With a robust drilling database, strong geophysical coverage, and a large, highly prospective land package anchored by the advancing Tyro target, West Point is well-positioned to benefit from DORA's ability to synthesize complex geological data into high-confidence exploration targets. The Company is looking to maximize the return on shareholder capital by focusing exploration efforts where the probability of success is highest. "We believe the use of VRIFY's AI-Assisted Mineral Discovery Platform, DORA, should help us define and prioritize the many step-out targets we have at Gold Chain," said Derek Macpherson, Executive Chairman of West Point Gold. "The use of AI will allow us to more efficiently take advantage of the extensive early-stage geologic work we have completed to date, hopefully accelerating our exploration process as we work to demonstrate Gold Chain's full potential." VRIFY CEO and Co-Founder, Steve de Jong, added, "West Point is a great example of the forward-thinking teams we're excited to partner with. They understand that leveraging AI and modern visualization isn't optional anymore, it's how the next generation of discoveries will be made." With mineral exploration entering a new era driven by artificial intelligence, West Point Gold's adoption of VRIFY reflects a broader strategic shift towards data-driven discovery, capital efficiency, and maximizing per-share value creation for shareholders. About West Point Gold Corp. West Point Gold Corp. (formerly Gold79 Mines Ltd.) is a publicly listed company focused on gold discovery and development at four prolific Walker Lane Trend projects covering Nevada and Arizona, USA. West Point Gold is focused on developing a maiden resource at its Gold Chain project in Arizona, while JV partner Kinross is advancing the Jefferson Canyon project in Nevada. About VRIFY VRIFY is redefining mineral exploration by putting the power of AI into the hands of geoscientists. DORA, VRIFY's AI-Assisted Mineral Discovery Platform, empowers technical teams to leverage the industry's largest proprietary exploration dataset and mineral-system-specific AI models to identify, rank, and validate high-potential targets faster, and with greater confidence. A high-growth software company trusted globally by over 170 mineral exploration and mining companies, VRIFY is shaping a new era of exploration and discovery. Learn more at: For further information regarding this press release, please contact: Aaron Paterson, Corporate Communications ManagerPhone: +1 (778) 358-6173Email: info@ Stay Connected with Us:LinkedIn: (Twitter): @westpointgoldUSFacebook: FORWARD-LOOKING STATEMENTS: Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events including, among others, assumptions about future prices of gold, silver, and other metal prices, currency exchange rates and interest rates, favourable operating conditions, political stability, obtaining government approvals and financing on time, obtaining renewals for existing licenses and permits and obtaining required licenses and permits, labour stability, stability in market conditions, availability of equipment, availability of drill rigs, and anticipated costs and expenditures. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to West Point Gold's ability to complete any payments or expenditures required under the Company's various option agreements for its projects; and other risks and uncertainties relating to the actual results of current exploration activities, the uncertainties related to resources estimates; the uncertainty of estimates and projections in relation to production, costs and expenses; risks relating to grade and continuity of mineral deposits; the uncertainties involved in interpreting drill results and other exploration data; the potential for delays in exploration or development activities; uncertainty related to the geology, grade and continuity of mineral deposits; the possibility that future exploration, development or mining results may vary from those expected; statements about expected results of operations, royalties, cash flows, financial position may not be consistent with the Company's expectations due to accidents, equipment breakdowns, title and permitting matters, labour disputes or other unanticipated difficulties with or interruptions in operations, fluctuating metal prices, unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and regulatory restrictions, including environmental regulatory restrictions. The possibility that future exploration, development or mining results will not be consistent with adjacent properties and the Company's expectations; operational risks and hazards inherent with the business of mining (including environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structural formations, cave-ins, flooding and severe weather); metal price fluctuations; environmental and regulatory requirements; availability of permits, failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; fluctuating gold prices; possibility of equipment breakdowns and delays, exploration cost overruns, availability of capital and financing, general economic, political risks, market or business conditions, regulatory changes, timeliness of government or regulatory approvals and other risks involved in the mineral exploration and development industry, and those risks set out in the filings on SEDAR+ made by the Company with securities regulators. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this corporate press release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, other than as required by applicable securities legislation. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
Yahoo
17 minutes ago
- Yahoo
Gold Pares Gains After Kremlin Confirms Meeting With Trump
(Bloomberg) -- Gold pared gains as markets weighed prospects for a truce in Ukraine after the Kremlin confirmed Presidents Vladimir Putin and Donald Trump would hold talks in the next few days. All Hail the Humble Speed Hump Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds Three Deaths Reported as NYC Legionnaires' Outbreak Spreads Major Istanbul Projects Are Stalling as City Leaders Sit in Jail PATH Train Service Resumes After Fire at Jersey City Station Bullion traded near $3,373 an ounce after earlier rising as much as 0.8%. Russia's announcement came a day after Putin met with Trump's envoy, Steve Witkoff, for almost three hours as the US pushed for an end to the Ukraine war. Bloomberg earlier reported that the Kremlin is considering options including an air truce, falling short of committing to a total ceasefire. Any easing of geopolitical tensions can curb demand for haven assets, pulling gold prices down. Traders are also watching US relations with global trading partners — marked this week by tariff hikes on Indian goods — and the likely nomination of a temporary Federal Reserve governor who may be more aligned with Trump's monetary agenda. Lower rates typically boost gold, which doesn't pay interest. Bullion has climbed almost 30% this year, though the bulk of those gains occurred in the first four months as geopolitical and trade tensions rattled the market. Spot gold rose 0.1% to $3,372.70 an ounce as of 12:05 p.m. in London. The Bloomberg Dollar Spot Index slipped 0.1%. Silver and palladium gained, while platinum fell. The Pizza Oven Startup With a Plan to Own Every Piece of the Pie Russia's Secret War and the Plot to Kill a German CEO AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay A High-Rise Push Is Helping Mumbai Squeeze in Pools, Gyms and Greenery Government Steps Up Campaign Against Business School Diversity ©2025 Bloomberg L.P. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
17 minutes ago
- Yahoo
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
